Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
- PMID: 40042059
- PMCID: PMC12105070
- DOI: 10.1111/all.16519
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Abstract
Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps (CRSwNP). Despite the limited availability of registered biologics for CRSwNP treatment in China, the country is experiencing rapid development in this field. It is imperative to standardize the application of biologic agents in CRSwNP management in preparation for their future integration into the CRSwNP care pathway. The Rhinology Group, Chinese Society of Otorhinolaryngology-Head and Neck Surgery; the Rhinology Group, Chinese Medical Doctor Association of Otorhinolaryngology-Head and Neck Surgery; and the Nasal and Ocular Allergy Group, Chinese Society of Allergy have convened an expert panel consisting of principal investigators experienced in clinical trials of biologic treatment for CRSwNP. This expert panel was assembled to discuss the application of biologic agents in patients with CRSwNP in China. Additionally, the latest findings on the pathogenesis of CRSwNP, mechanisms of biologic agents, and efficacy and safety of biologic treatment in patients with CRSwNP were reviewed, with a special emphasis on research evidence from China. The expert panel reached a consensus on several critical issues, including criteria for the prescription, treatment course, and efficacy evaluation from a Chinese perspective. This position paper aims to guide Chinese physicians in the use of biologic agents for patients with CRSwNP. As our experience with biologic treatment continues to grow, this position paper will be further updated.
Keywords: China; biologics; chronic rhinosinusitis with nasal polyps; monoclonal antibody; treatment.
© 2025 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- Fokkens W. J., Lund V. J., Hopkins C., et al., “European Position Paper on Rhinosinusitis and Nasal Polyps 2020,” Rhinology 58, no. Suppl S29 (2020): 1–464. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 2022YFC2504100/National Key R&D Program of China
- 82025010/National Natural Science Foundation of China
- 82371115/National Natural Science Foundation of China
- 82471135/National Natural Science Foundation of China
- 82171111/National Natural Science Foundation of China
- Z221100007422009/Beijing Municipal Science and Technology Project
- Z211100002921057/Beijing Municipal Science and Technology Project
- CFH2022-1-1091/Capital's Funds for Health Improvement and Research
- JYY2023-1/Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes, Beijing Municipal Health Commission
LinkOut - more resources
Full Text Sources
Medical
Research Materials
